Cargando…
H5N1 Influenza Vaccine Formulated with AS03(A) Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses
OBJECTIVE: Adjuvantation of an H5N1 split-virion influenza vaccine with AS03(A) substantially reduces the antigen dose required to produce a putatively protective humoral response and promotes cross-clade neutralizing responses. We determined the effect of adjuvantation on antibody persistence and B...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132412/ https://www.ncbi.nlm.nih.gov/pubmed/21174144 http://dx.doi.org/10.1007/s10875-010-9490-6 |
_version_ | 1782207818899652608 |
---|---|
author | Moris, Philippe van der Most, Robbert Leroux-Roels, Isabel Clement, Frédéric Dramé, Mamadou Hanon, Emmanuel Leroux-Roels, Geert G. Van Mechelen, Marcelle |
author_facet | Moris, Philippe van der Most, Robbert Leroux-Roels, Isabel Clement, Frédéric Dramé, Mamadou Hanon, Emmanuel Leroux-Roels, Geert G. Van Mechelen, Marcelle |
author_sort | Moris, Philippe |
collection | PubMed |
description | OBJECTIVE: Adjuvantation of an H5N1 split-virion influenza vaccine with AS03(A) substantially reduces the antigen dose required to produce a putatively protective humoral response and promotes cross-clade neutralizing responses. We determined the effect of adjuvantation on antibody persistence and B- and T-cell-mediated immune responses. METHODS: Two vaccinations with a split-virion A/Vietnam/1194/2004 (H5N1, clade 1) vaccine containing 3.75–30 μg hemagglutinin and formulated with or without adjuvant were administered to groups of 50 volunteers aged 18–60 years. RESULTS: Adjuvantation of the vaccine led to better persistence of neutralizing and hemagglutination-inhibiting antibodies and higher frequencies of antigen-specific memory B cells. Cross-reactive and polyfunctional H5N1-specific CD4 T cells were detected at baseline and were amplified by vaccination. Expansion of CD4 T cells was enhanced by adjuvantation. CONCLUSION: Formulation of the H5N1 vaccine with AS03(A) enhances antibody persistence and induces stronger T- and B-cell responses. The cross-clade T-cell immunity indicates that the adjuvanted vaccine primes individuals to respond to either infection and/or subsequent vaccination with strains drifted from the primary vaccine strain. |
format | Online Article Text |
id | pubmed-3132412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-31324122011-08-24 H5N1 Influenza Vaccine Formulated with AS03(A) Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses Moris, Philippe van der Most, Robbert Leroux-Roels, Isabel Clement, Frédéric Dramé, Mamadou Hanon, Emmanuel Leroux-Roels, Geert G. Van Mechelen, Marcelle J Clin Immunol Article OBJECTIVE: Adjuvantation of an H5N1 split-virion influenza vaccine with AS03(A) substantially reduces the antigen dose required to produce a putatively protective humoral response and promotes cross-clade neutralizing responses. We determined the effect of adjuvantation on antibody persistence and B- and T-cell-mediated immune responses. METHODS: Two vaccinations with a split-virion A/Vietnam/1194/2004 (H5N1, clade 1) vaccine containing 3.75–30 μg hemagglutinin and formulated with or without adjuvant were administered to groups of 50 volunteers aged 18–60 years. RESULTS: Adjuvantation of the vaccine led to better persistence of neutralizing and hemagglutination-inhibiting antibodies and higher frequencies of antigen-specific memory B cells. Cross-reactive and polyfunctional H5N1-specific CD4 T cells were detected at baseline and were amplified by vaccination. Expansion of CD4 T cells was enhanced by adjuvantation. CONCLUSION: Formulation of the H5N1 vaccine with AS03(A) enhances antibody persistence and induces stronger T- and B-cell responses. The cross-clade T-cell immunity indicates that the adjuvanted vaccine primes individuals to respond to either infection and/or subsequent vaccination with strains drifted from the primary vaccine strain. Springer US 2010-12-21 2011 /pmc/articles/PMC3132412/ /pubmed/21174144 http://dx.doi.org/10.1007/s10875-010-9490-6 Text en © The Author(s) 2010 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Article Moris, Philippe van der Most, Robbert Leroux-Roels, Isabel Clement, Frédéric Dramé, Mamadou Hanon, Emmanuel Leroux-Roels, Geert G. Van Mechelen, Marcelle H5N1 Influenza Vaccine Formulated with AS03(A) Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses |
title | H5N1 Influenza Vaccine Formulated with AS03(A) Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses |
title_full | H5N1 Influenza Vaccine Formulated with AS03(A) Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses |
title_fullStr | H5N1 Influenza Vaccine Formulated with AS03(A) Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses |
title_full_unstemmed | H5N1 Influenza Vaccine Formulated with AS03(A) Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses |
title_short | H5N1 Influenza Vaccine Formulated with AS03(A) Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses |
title_sort | h5n1 influenza vaccine formulated with as03(a) induces strong cross-reactive and polyfunctional cd4 t-cell responses |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132412/ https://www.ncbi.nlm.nih.gov/pubmed/21174144 http://dx.doi.org/10.1007/s10875-010-9490-6 |
work_keys_str_mv | AT morisphilippe h5n1influenzavaccineformulatedwithas03ainducesstrongcrossreactiveandpolyfunctionalcd4tcellresponses AT vandermostrobbert h5n1influenzavaccineformulatedwithas03ainducesstrongcrossreactiveandpolyfunctionalcd4tcellresponses AT lerouxroelsisabel h5n1influenzavaccineformulatedwithas03ainducesstrongcrossreactiveandpolyfunctionalcd4tcellresponses AT clementfrederic h5n1influenzavaccineformulatedwithas03ainducesstrongcrossreactiveandpolyfunctionalcd4tcellresponses AT dramemamadou h5n1influenzavaccineformulatedwithas03ainducesstrongcrossreactiveandpolyfunctionalcd4tcellresponses AT hanonemmanuel h5n1influenzavaccineformulatedwithas03ainducesstrongcrossreactiveandpolyfunctionalcd4tcellresponses AT lerouxroelsgeertg h5n1influenzavaccineformulatedwithas03ainducesstrongcrossreactiveandpolyfunctionalcd4tcellresponses AT vanmechelenmarcelle h5n1influenzavaccineformulatedwithas03ainducesstrongcrossreactiveandpolyfunctionalcd4tcellresponses |